AstraZeneca-Merck Lynparza gets EMA's positive recommendation

Drugmakers AstraZeneca Plc and Merck & Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer.

from Reuters: Health News https://ift.tt/2XmwWYg
via IFTTT